FDA Calendar

Company Name Eli Lilly And Co.
Drug Name Abemaciclib (NDA)
Event Name FDA decision on Abemaciclib for the treatment of advanced breast cancer
Event Date Q1 2018
Outcome Date 09/28/2017
Outcome FDA approved Abemaciclib under brand name Verzenio for use in combination with Faslodex for patients with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy on Sep.28, 2017
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
Return to FDA Calendar